Page 88 - குறிப்பு தொடர்பாக முன்னோக்கி பார்க்கிறது அறிக்கைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from குறிப்பு தொடர்பாக முன்னோக்கி பார்க்கிறது அறிக்கைகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In குறிப்பு தொடர்பாக முன்னோக்கி பார்க்கிறது அறிக்கைகள் Today - Breaking & Trending Today

Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance


Share this article
Share this article
DUBLIN, Feb. 25, 2021 /PRNewswire/  Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance.
I am proud of all that the Endo team achieved in a very challenging year. We made significant progress in advancing our strategic priorities, delivered solid financial performance, rapidly responded to the COVID-19 pandemic and advanced our ESG-related actions, said Blaise Coleman, President and Chief Executive Officer at Endo.
Looking ahead, we remain committed to expanding and enhancing our portfolio through focused investments, including the anticipated spring 2021 launch of QWO ....

Blaise Coleman , Biospecifics Technologies Corp , Branded Pharmaceuticals , Company Income , Generic Pharmaceuticals , Exchange Commission , International Pharmaceuticals , Endo International , Chief Executive Officer , Months Ended December , Ended December , Diluted Net Income , Net Income , Continuing Operations , Diluted Weighted Average Shares , Adjusted Diluted Weighted Average Shares , Adjusted Income , Sterile Injectables , Biospecifics Technologies , Note Regarding Forward Looking Statements , Operating Expenses , Total Revenues , Nasal Spray , Condensed Consolidated Statement , Condensed Consolidated Balance Sheet , Cash Flow ,

Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results


Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
– Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 –
– Ended 2020 with $213.2 million in cash, cash equivalents and investments –
– Company to host conference call and webcast today at 8:00 AM ET –
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.
“2020 proved to be a year of important pipeline execution and corporate development at Jounce despite the challenges presented by the COVID-19 pandemic. As we enter 2021, we are strongly positioned to execute on our two proof of concep ....

United Kingdom , Malin Deon , Mark Yore , Richard Murray , Exchange Commission , Society For Immunotherapy Of Cancer , Gilead Sciences Inc , Jounce Therapeutics Inc , Jounce Therapeutics , Annual Meeting , Gilead Sciences , Full Year , Webcast Information , Translational Science , Note Regarding Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report , Consolidated Balance Sheet Data , Media Contacts , ஒன்றுபட்டது கிஂக்டம் , மாலின் டியான் , குறி முந்தைய , ரிச்சர்ட் முர்ரே , பரிமாற்றம் தரகு , சமூகம் க்கு நோயெதிர்ப்பு சிகிச்சை ஆஃப் புற்றுநோய் , கிலியட் அறிவியல் இன்க் ,